Controlled release exactly where and when you want it.

BDD has developed an erosion based controlled release technology that provides unrivalled control of drug release at a pre-defined time with no release of drug prior to the pulse. The technology is an erodible barrier layer that is wrapped around a drug containing core to give a tablet in tablet dose form. The barrier layer is designed to erode at a controlled rate until eventually the drug is released from the core tablet, and the length of the delay period can be tailored between 2 and 8 hours by simply changing excipient ratios.

 

The barrier layer works independently of the core so can be applied to almost any drug where there is a therapeutic need, with minimal development. The release can be sustained or pulsed release giving unparalleled versatility.

 

The OralogiK™ barrier layer can be readily film coated, allowing addition of an immediate release dose which can be the same or different to the drug in the core tablet.

 

These wide-ranging formulation attributes permit the realisation of complex delivery profiles in which one or more drugs can be combined into a single tablet, using proven manufacturing technologies to achieve new therapeutic objectives, previously unattainable.

Slide1
Slide2
Slide3
Slide4
Slide5
Slide6
Slide7
Slide8
Slide9
Slide10

BDD Pharma Ltd.

Clinical Site:
Glasgow Royal Infirmary
84 Castle St
Glasgow
G4 0SF, UK

Formulation site:
Bio-City Scotland

Bo'ness Road

Chapelhall, Newhouse

ML1 5UH, UK

Contact Us

Clinical Site. +44 (0)141 552 8791

Formulation site. +44 (0)141 552 7752

email. enquiries@bddpharma.com

 

Social Media

  • LinkedIn - White Circle
  • Twitter - White Circle
  • YouTube - White Circle
  • Facebook - White Circle

Registered in Scotland No. 212868        Privacy Policy     Acceptable Use     Terms of Use   

@2021 BDD Ltd

Slide5